Jyong Biotech Ltd MENS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.21
- Day Range
- $2.25–2.25
- 52-Week Range
- $1.44–64.67
- Bid/Ask
- $2.15 / $2.29
- Shares Outstanding
- 74.23M
- Market Cap
- $164.06M
- Volume/Avg
- 31 / 100,974
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Jyong Biotech Ltd is research and develop new drugs for today's great unmet medical needs and planned to manufacture and sell new drugs after receiving regulatory approval. It is a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. The Group operates and manages its business as a single segment in the research and development of novel therapeutics targeting unmet needs. The company's product pipeline includes MCS-2, PCP, IC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 27
Valuation
|
Metric
|
MENS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MENS
|
|---|---|
Quick Ratio | 0.42 |
Current Ratio | 0.45 |
Interest Coverage | −1.08 |
Quick Ratio
MENS
Profitability
|
Metric
|
MENS
|
|---|---|
Return on Assets (Normalized) | −21.63% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
MENS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|Q>%$#J | LOCK|Kk^L | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|z%m?w$ | LOCK|?>kz$ | $70B | |||
| argenx SE ADR
ARGX
| LOCK|<v#&b@J | LOCK|&Vh | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>C%@R?B | LOCK|&qBc | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?thJ#l | LOCK|t< | $36B | |||
| Moderna Inc
MRNA
| LOCK|kYnzNT$ | LOCK|FL | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|ShxY&zCb | LOCK|@@MG | $25B | |||
| Incyte Corp
INCY
| LOCK|J>r!Z<W | LOCK|>>@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|MFdrM?h | LOCK|?&L | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|^b@$Sd | LOCK|&# | $16B |
United States